Acute Kidney Injury and Acute Kidney Disease in COVID-19

Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) in Patients With Coronavirus Disease 2019 (COVID-19)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04353583

Enrollment

900

Registered

2020-04-20

Start date

2020-04-21

Completion date

2025-02-01

Last updated

2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Corona Virus Infection

Brief summary

Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Detailed description

Beginning in December 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (SARS-CoV-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1\) Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria

Exclusion criteria

1. Patients aged less than 18 years 2. Patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate \<30 ml/min/1.73 m2) 3. Patients receiving maintenance dialysis 4. Recipients of solid-organ transplantation

Design outcomes

Primary

Measure	Time frame	Description
Incidence of AKI	30 days post-hospital admission	Serial assessment of serum creatinine and urine output
Cystatin C as indicator of mortality	30 days post-hospital admission	All-cause mortality
Cystatin C as indicator of renal disease	30 days post-hospital admission	AKI and acute kidney disease (AKD)
Cystatin C as indicator of respiratory illness	30 days post-hospital admission	Ventilator-free days
Cystatin C as indicator of disease severity	30 days post-hospital admission	Rate of intensive care unit admission

Countries

Germany

Outcome results